Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

Alnylam Pharmaceuticals ALNY -3.78% Get Free Report has outperformed the market over the past 15 years by 8.52% on an ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best long term growth stocks to buy according to billionaires. As per ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...